Pharmacological and psychological interventions for antisocial personality disorder - Results of two cochrane reviews

European Psychiatric Review

Volumn 4, Issue 1, 2011, Pages 52-58

  Gibbon, Simon ^a   Völlm, Birgit A ^b   Duggan, Conor ^b   Khalifa, Najat ^b   Stoffers, Jutta ^c,d   Huband, Nick ^b   Ferriter, Michael ^b   Lieb, Klaus ^d  

^a St Andrews Healthcare   (United Kingdom)

^b NOTTINGHAMSHIRE HEALTHCARE NHS TRUST   (United Kingdom)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Antisocial personality disorder; Dissocial personality disorder; Pharmacological interventions; Psychological interventions; Systematic review; Treatment

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CARBAMAZEPINE; DESIPRAMINE; NALTREXONE; NORTRIPTYLINE; PHENYTOIN; PLACEBO; VALPROATE SEMISODIUM; VALPROIC ACID;

CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COGNITIVE THERAPY; DRUG EFFICACY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PSYCHOEDUCATION; PSYCHOPATHY; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84856259556     PISSN: 17581354     EISSN: 17581362     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. American Psychiatric Association (2000), DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders: Text Revision, Arlington, Virginia, USA
2. World Health Organization (WHO), The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines, Geneva: WHO, 1992
3. Coid J, Yang M, Tyrer P, et al., Prevalence and correlates of personality disorder in Great Britain, Br J Psychiatry 2006;188:423-31.
4. Moran P, The epidemiology of antisocial personality disorder, Social Psychiatry and Psychiatric Epidemiology, 1999;34(5):231-42
5. Singleton N, Melzer H, Gatward R, Psychiatric morbidity among prisoners in England and Wales, London: HM Stationery Office, 1998
6. Robins LN, Tipp J, Przybeck T, Antisocial personality. In: Robins LN, Regier DA ed(s), Psychiatric disorders in America, New York: Free Press, 1991.
7. Home Office, Reconviction of offenders sentenced or discharged from prison in 1994, England and Wales: Home Office Statistical Bulletin5/99, London: Home Office, 1999
8. Davies S, Clarke M, Hollin C, Duggan C, Long-term outcomes after discharge from medium secure care: a cause for concern, Br J Psychiatry, 2007;191:70-4
9. Skodol AE, Oldham JM, Bender DS, et al., Dimensional representations of DSM-IV personality disorders: relationships to functional impairment, American Journal of Psychiatry, 2005;162(10):1919-25.
10. Myers MG, Stewart DG, Brown SA, Progression from conduct disorder to antisocial personality disorder following treatment for adolescent substance abuse, American Journal of Psychiatry, 1998; 155:479-85
11. Black DW, Baumgard CH, Bell SE, Kao C, Death rates in 71 men with antisocial personality disorder: A comparison with general population mortality, Psychosomatics, 1996;37(2):131-6
12. Newton-Howes G, Tyrer P, Johnson T, Personality disorder and the outcome of depression: meta-analysis of published studies, Br J Psychiatry, 2006;188:13-20
13. Bateman AW, Tyrer P, Psychological treatment for personality disorders, Advances in Psychiatric Treatment, 2004;10:378-88
14. Linehan MM, The skills training manual for treating borderline personality disorder, New York: Guilford Press, 1993
15. Denman C, Cognitive analytic therapy, Advances in Psychiatric Treatment, 2001;7:243-56
16. Campling P, Therapeutic communities, Advances in Psychiatric Treatment, 2001;7:365-72
17. Tyrer P, Kramo K, Miloseka K, Seivewright H, The place for nidotherapy in psychiatric practice, Psychiatric Bulletin, 2007;31:1-3
18. Soloff PH, Algorithms for pharmacological treatment of personality dimensions. Symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation, Bulletin of the Menninger Clinic, 1998;62:195-214.
19. Tyrer P, Tom B, Byford S, et al., Differential effects of manual assisted cognitive behavior therapy in the treatment of recurrent deliberate self-harm and personality disturbance: the POPMACT study, J Pers Disord, 2004; 18(1):102-16.
20. Markovitz PJ, Recent trends in the pharmacotherapy of personality disorders, J Pers Disord, 2004;18(1):90-101.
21. Coccaro EF, Kavoussi RJ, Sheline YI, et al., Impulsive aggression in personality disorder correlates with tritiated paroxetine binding in the platelet, Arch Gen Psychiatry, 1996;53:531-6.
22. Sugden SG, Kile SJ, Hendren R, Neurodevelopmental pathways to aggression: a model to understand and target treatment in youth, J Neuropsychiatry Clin Neurosci, 2006;18(3):302-17
23. Dolan B, Coid J, Psychopathic and anti-social personality disorders: treatment and research Issues, London: Gaskell, 1993.
24. Warren F, McGauley G, Norton K, et al., Review of treatments of severe personality disorder, Home Office Online Report 30/03 (www.homeoffice.gov.uk/rds/pdfs2/rdsolr3003.pdf) 2003 (accessed 28 January 2011).
25. National Institute of Health and Clinical Excellence, Antisocial personality disorder: treatment, management and prevention (NICE Guideline 77) www.nice.org.uk/CG77 (accessed 28 January 2011), London: National Institute of Health and Clinical Excellence, 2009.
26. Gibbon S, Duggan C, Stoffers J, et al., Psychological interventions for antisocial personality disorder, Cochrane Database of Systematic Reviews 2010, Issue 6. Art.No.:CD007668.DOI: 10.1002/14651858.CD007668.pub2.
27. Khalifa N, Duggan C, Stoffers J, et al., Pharmacological interventions for antisocial personality disorder, Cochrane Database of Systematic Reviews 2010, Issue 8. Art. No.: CD007667. DOI: 10.1002/14651858.CD007667.pub2.
28. BNF 2008 Joint Formulary Committee, British National Formulary, [edition number 56] ed. London: British Medical Association and Royal Pharmaceutical Society, 2008.
29. The Nordic Cochrane Centre, The Cochrane Collaboration, Review Manager (RevMan). 5.0, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
30. Higgins JPT, Green S, ed(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0, The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org (accessed 28 January 2010).
31. Davidson KM, Tyrer P, Tata P, et al., Cognitive behaviour therapy for violent men with antisocial personality disorder in the community: an explanatory randomized controlled trial, Psychological Medicine, 2009;39:569-77.
32. Woodall WG, Delaney HD, Kunitz SJ, et al., A randomized trial of a DWI intervention program for first offenders: intervention outcomes and interactions with antisocial personality disorder among a primarily American-Indian sample, Alcoholism, Clin Exp Med, 2007;31(6):974-87.
33. Marlowe DB, Festinger DS, Dugosh KL, et al., Adapting judicial supervision to the risk level of drug offenders: discharge and 6-month outcomes from a prospective matching study, Drug and Alcohol Dependence, 2007;88(Suppl 2):S4-S13.
34. Huband N, McMurran M, Evans C, Duggan C, Social problem solving plus psychoeducation for adults with personality disorder: pragmatic randomised controlled trial, Br J Psychiatry, 2007;190:307-13
35. Neufeld KJ, Kidorf MS, Kolodner K, et al., A behavioral treatment for opioid-dependent patients with antisocial personality, Journal of Substance Abuse Treatment, 2008;34:101-11.
36. Ball SA, Cobb-Richardson P, Connolly AJ, et al., Substance abuse and personality disorders in homeless drop-in center clients: symptom severity and psychotherapy retention in a randomized clinical trial, Compr Psychiatry, 2005;46(5): 371-9.
37. Messina N, Farabee D, Rawson R, Treatment responsivity of cocaine-dependent patients with antisocial personality disorder to cognitive-behavioral and contingency management interventions, J Consult Clin Psychol, 2003;71(2):320-30
38. Woody GE, McLellan AT, Luborsky L, O'Brien CP, Sociopathy and psychotherapy outcome, Arch Gen Psychiatry, 1985;42 (11):1081-6
39. McKay JR, Alterman AI, Cacciola JS, et al., Prognostic significance of antisocial personality disorders in cocainedependent patients entering continuing care, J Nerv Ment Dis, 2000;188:287-96.
40. Tyrer P, Tom B, Byford S, et al., Differential effects of manual assisted cognitive behavior therapy in the treatment of recurrent deliberate self-harm and personality disturbance: the POPMACT study, J Pers Disord, 2004;18(1):102-16.
41. Havens JR, Cornelius LJ, Ricketts EP, et al., The effect of a case management intervention on drug treatment entry among treatment-seeking injection drug users with and without comorbid antisocial personality disorder, Journal of Urban Health, 2007;84(2):267-71.
42. Arndt IO, McClellan AT, Dorozynsky L, et al., Desipramine treatment for cocaine dependence: role of antisocial personality disorder, J Nerv Ment Dis, 1994;182(3):151-6.
43. Leal J, Ziedonis D, Kosten T, Antisocial personality disorder as a prognostic factor for pharmacotherapy of cocaine dependence, Drug and Alcohol Dependence, 1994;35:31-5
44. Powell BJ, Campbell JL, Landon JF, et al., A double-blind, placebo-controlled study of nortriptyline and bromocriptine in male alcoholics subtyped by comorbid psychiatric disorders, Alcoholism, Clin Exp Med, 1995;19(2):462-8.
45. Barratt ES, Stanford MS, Felthous AR, Kent TA, The effects of phenytoin on impulsive and premeditated aggression: a controlled study, Journal of Clinical Psychopharmacology, 1: 1997461709, 1997;17(5):341-9
46. Stanford MS, Houston RJ, Mathias CW, Greve KW, et al., A double-blind placebo-controlled crossover study of phenytoin in individuals with impulsive aggression, Psychiatry Research, 2001;103(2-3):193-203.
47. Hollander E, Tracy KA, Swann AC, et al., Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders, Neuropsychopharmacology, 2003;28(6):1186-97.
48. Stanford MS, Helfritz LE, Conklin SM, et al., A comparison of anticonvulsants in the treatment of impulsive aggression, Experimental and Clinical Psychopharmacology, 2005;13(1):72-7.
49. Ralevski E, Ball S, Nich C, et al., The impact of personality disorders on alcohol-use outcomes in a pharmacotherapy trial for alcohol dependence and comorbid Axis I disorders, American Journal on Addictions, 2007;16(6):443-9.
50. Lieb K, Völlm B, Rücker G, et al., Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials, Br J Psychiatry, 2010;196(1):4-12.